Telos Capital Management
VRTX icon

Telos Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Telos Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.7M Sell
24,203
-86
-0.4% -$44K 1.11% 29
2026
Q2 		$12.1M Buy
24,289
+1,055
+5% +$468K 1.06% 30
2026
Q1 		$10.4M Buy
23,234
+858
+4% +$400K 0.99% 32
2025
Q4 		$10.1M Buy
22,376
+1,188
+6% +$512K 0.95% 31
2025
Q3 		$8.3M Buy
21,188
+1,946
+10% +$813K 0.8% 43
2025
Q2 		$8.57M Buy
19,242
+1,068
+6% +$492K 0.87% 36
2025
Q1 		$8.81M Buy
18,174
+547
+3% +$255K 0.96% 30
2024
Q4 		$7.1M Buy
17,627
+1,605
+10% +$744K 0.76% 44
2024
Q3 		$7.45M Buy
16,022
+6
+0% +$2.88K 0.78% 43
2024
Q2 		$7.51M Buy
16,016
+546
+4% +$237K 0.83% 38
2024
Q1 		$6.47M Buy
15,470
+397
+3% +$168K 0.73% 45
2023
Q4 		$6.13M Buy
15,073
+237
+2% +$87.6K 0.75% 44
2023
Q3 		$5.16M Sell
14,836
-90
-0.6% -$31.5K 0.72% 45
2023
Q2 		$5.25M Sell
14,926
-333
-2% -$112K 0.7% 50
2023
Q1 		$4.81M Sell
15,259
-841
-5% -$252K 0.67% 59
2022
Q4 		$4.65M Sell
16,100
-43
-0.3% -$13.1K 0.68% 57
2022
Q3 		$4.67M Sell
16,143
-622
-4% -$179K 0.77% 46
2022
Q2 		$4.72M Sell
16,765
-175
-1% -$46.8K 0.72% 49
2022
Q1 		$4.42M Sell
16,940
-159
-0.9% -$37.7K 0.57% 64
2021
Q4 		$3.76M Buy
17,099
+581
+4% +$113K 0.47% 72
2021
Q3 		$3M Buy
16,518
+1,156
+8% +$226K 0.41% 80
2021
Q2 		$3.1M Buy
+15,362
New +$3.21M 0.41% 80

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Telos Capital Management's VRTX Position: Q3 2026 in Review

Telos Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.35% in Q3 2026, selling an estimated $44K and leaving 24,203 shares worth $12.7M. The position accounts for 1.11% of the portfolio, ranked #29.

Telos Capital Management first reported a position in VRTX in Q2 2021 and has held it in 22 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Telos Capital Management held 24,203 shares of Vertex Pharmaceuticals worth $12.7M as of Q3 2026.
  • Telos Capital Management sold 86 Vertex Pharmaceuticals shares in Q3 2026, an estimated $44K.
  • Vertex Pharmaceuticals made up 1.11% of Telos Capital Management's portfolio in Q3 2026, its #29 holding.
  • Telos Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 22 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Telos Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.